Newswire (Published: Friday, October 11, 2019, Received: Friday, October 11, 2019, 4:07:20 PM CDT)

Word Count: 477

2019 OCT 11 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Daily -- Data detailed on Oncology - Prostate Cancer have been presented. According to news originating from Istanbul, Turkey, by NewsRx correspondents, research stated, “Ga-and F-labeled prostate-specific membrane antigen (PSMA) molecules have created new opportunities for the unmet diagnostic needs in prostate cancer. The purpose of this article is to give an overview of studies that have examined the role of PSMA PET in treatment planning for prostate cancer patients with biochemical recurrence (BCR).”

Our news journalists obtained a quote from the research from Sisli Etfal Education and Research Hospital, “Medline, Embase, Web of Science, Google Scholar, and Cochrane Central were searched for relevant articles. After excluding the articles that did not fulfill the required criteria, we included in this review 12 publications that reported the impact of PSMA PET on the treatment plan for prostate cancer patients with BCR. All studies in our review emphasized the impact of PSMA PET images on therapy management in prostate cancer patients with BCR. Overall, the impact of PSMA PET/CT on therapy management varied between 30% and 76% among the 1,346 patients included in the review. Upstaging was reported in 32%-67% of the patients. Patients with low prostate-specific antigen values (<0.5 ng/mL) also demonstrated positive lesions, which could not have been detected by means of conventional imaging techniques. Important modifications to the original treatment plan included avoidance of systemic therapy (17%-40%) and PET-directed local therapy (in 60% of the patients). PSMA imaging demonstrated a high clinical impact in patients with BCR, with modifications to the original treatment plan occurring among half the patients.”

According to the news editors, the research concluded: “Detecting recurrence in BCR can prevent unnecessary toxicity and lead to individualized therapy.”

For more information on this research see: Bridging the Imaging Gap: PSMA PET/CT Has a High Impact on Treatment Planning in Prostate Cancer Patients with Biochemical Recurrence-A Narrative Review of the Literature. Journal of Nuclear Medicine, 2019;60(10):1394-1398. Journal of Nuclear Medicine can be contacted at: Soc Nuclear Medicine Inc, 1850 Samuel Morse Dr, Reston, VA 20190-5316, USA.

The news correspondents report that additional information may be obtained from O. Ekmekcioglu, Nuclear Medicine Department, Sisli Etfal Education and Research Hospital, Istanbul, Turkey. Additional authors for this research include M. Busstra, N.D. Klass and F. Verzijlbergen.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.2967/jnumed.118.222885. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

The publisher’s contact information for the Journal of Nuclear Medicine is: Soc Nuclear Medicine Inc, 1850 Samuel Morse Dr, Reston, VA 20190-5316, USA.

(Our reports deliver fact-based news of research and discoveries from around the world.)

Industries

Healthcare
      Healthcare Facilities
            Hospitals

Places

North America
Western Asia
Turkey
United States
Americas
Asia
Europe
Virginia
Istanbul
Reston

Subjects

Science and Technology
      Scientific Research
            Medical Research
Health and Wellness
      Medical Conditions and Diseases
            Cancer
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer
      Health Sciences
            Medical Research
Life and Society
      Education
            Issues in Education